Novo Nordisk Launches Wegovy Pill in US
Analysis based on 8 articles · First reported Jan 05, 2026 · Last updated Jan 05, 2026
The launch of Novo Nordisk's Wegovy pill is expected to intensify competition in the weight-loss drug market, directly impacting Eli Lilly and Company's market share and stock performance. The focus on cash-paying customers and government deals also signals a shift in drug pricing models, potentially affecting healthcare insurers and telehealth providers.
Novo Nordisk has launched its once-daily Wegovy pill in the United States, offering various doses at competitive prices for self-paying patients. This move follows the pill's approval by the United States — Food and Drug Administration and aims to help Novo Nordisk regain market ground from rival Eli Lilly and Company. The Wegovy pill, containing semaglutide, offers an alternative to injectable medications and is expected to attract new consumers, especially cash-paying customers without insurance coverage. Shares of Novo Nordisk rose following the announcement, while Eli Lilly and Company's shares declined. A deal with Donald Trump will also provide discounted starter doses for United States — Medicare and United States — Medicaid enrollees and cash payers through the new TrumpRx site. Novo Nordisk has built up supplies to prevent shortages, a problem faced with its injectable Wegovy.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard